Adverse events (AEs)

American Society of Clinical Oncology (ASCO)

Area under the curve (AUC)

Confidence interval (CI)

Epithelial tubo-ovarian cancer (ETOC)

Estimated glomerular filtration rate (eGFR)

Every four weeks (Q4W)

Every three weeks (Q3W)

Granulocyte colony-stimulating factor (GCSF)

Gynecologic Cancer InterGroup (GCIG)

Gynecologic Oncology Group (GOG)

Hazard ratio (HR)

International Collaboration on Ovarian Neoplasms (ICON)

International Federation of Gynecology and Obstetrics (FIGO)

Interval cytoreductive surgery (ISC)

Intravenous (IV)

Intraperitoneal (IP)

Japanese Gynecologic Oncology Group (JGOG)

National Cancer Institute’s Common Terminology Criteria for Adverse Events (NCI-CTCAE)

National comprehensive Cancer Network (NCCN)

Neoadjuvant chemotherapy (NACT)

Net health benefits (NHBs)

Magnetic resonance image (MRI)

Multicentre Italian Trials in Ovarian cancer (MITO)

Overall survival (OS)

Poly(ADP-ribose) polymerase (PARP) inhibitors (PARP inhibitors)

Primary peritoneal serous carcinoma (PPSC)

Primary cytoreductive surgery (PSC)

Primary debulking surgery (PDS)

Progression-free survival (PFS)

Progressive disease (PD)

Quality of life (QOL)

Response Evaluation Criteria in Solid Tumors (RECIST)